00:00Cellular therapies, in particular the therapies with CAR-T cells, have shown a great advance,
00:13which historically has been applied to a particular type of lymphomas, non-Hodgkin aggressive lymphomas,
00:23and which is the reason for our discussion today, also as an application to another neoplastic pathology of the middle osseo,
00:35which is represented by the multiple myeloma.
00:38We are talking about an indication for patients who have already been exposed to the three main agents
00:46in use in the multiple myeloma therapy and who have shown a refractariousness to the last line of therapy.
00:55These patients historically, over the last few years, have represented a satisfactory therapeutic need
01:03with a survival duration of less than a year and which can also be no more than six months.
01:11Therefore, having at our disposal a therapy that goes beyond resistance mechanisms,
01:17which is able to offer responses in about 80% of a population of patients who have used any other therapeutic alternative,
01:28and to offer a survival duration of about two years with a good quality of life,
01:36because the therapy we are talking about is a therapy with a single infusion,
01:41certainly represents a great success, but above all a great therapeutic possibility that can be offered to our patients.
Comments